Hosted on MSN58m
FDA grants ODD status to Zai Lab’s lung cancer treatmentThe US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to Zai Lab’s delta-like ligand 3 (DLL3) antibody-drug conjugate (ADC), ZL-1310, for small cell lung cancer (SCLC).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback